2012
Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia.
Barnett PG, Scott JY, Krystal JH, Rosenheck RA. Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia. The Journal Of Clinical Psychiatry 2012, 73: 696-702. PMID: 22697193, DOI: 10.4088/jcp.11m07070.Peer-Reviewed Original ResearchMeSH KeywordsAntipsychotic AgentsComparative Effectiveness ResearchCost-Benefit AnalysisDelayed-Action PreparationsDouble-Blind MethodDrug CostsFemaleHealth Care CostsHospitalizationHumansInjectionsKaplan-Meier EstimateMaleMiddle AgedModels, EconometricPsychotic DisordersRisperidoneSchizophreniaUnited StatesVeteransConceptsTotal health care costsHealth care costsLAI risperidoneMedication costsControl groupCare costsVeterans Health Administration patientsHealth care utilizationHealth Related QualityStructured Clinical InterviewUS Medicaid programCase report formsMultisite clinical trialQuality of WellExperimental groupOral antipsychoticsAdverse eventsCare utilizationInjectable risperidoneOutpatient costsHospitalization costsClinical trialsRelated qualityLAI groupPhysician's choice
1999
Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients
Krystal J, D'Souza D, Madonick S, Petrakis I. Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients. Schizophrenia Research 1999, 35: s35-s49. PMID: 10190224, DOI: 10.1016/s0920-9964(98)00162-5.Peer-Reviewed Original ResearchConceptsSchizophrenic patientsSubstance abuseTerms of rehospitalizationComorbid substance abuseExacerbation of symptomsHealth care expensesSelf-medication hypothesisBetter prognosisMedical illnessPharmacotherapeutic approachesRational pharmacotherapyNonschizophrenic populationsPatientsVocational functionIllicit substancesCare expensesAbuseVulnerability hypothesisRehospitalizationExacerbationMedicationsPharmacotherapyPrognosisPsychostimulantsIllness